PPT-Paradigm Shift in the Management of Metastatic Castration-Sensitive Prostate

m CSPC 1 Neal Shore MD FACS Carolina Urologic Research Center Myrtle Beach SC Alicia Morgans MD MPH Northwestern University Chicago IL PROSTATE CANCER IS HORMONE DEPENDENT 2 Huggins CB Nobel lecture Available from . D. ocking. Monique Pairis-Garcia BS, DVM, PhD, . mdpairis@iastate.edu. . Anna Johnson BSc, MSc, PhD, . johnsona@iastate.edu. . Department of Animal Science,. Iowa State University. Ames, IA. 1. Objectives. D. ocking. Monique Pairis-Garcia BS, DVM, PhD, . mdpairis@iastate.edu. . Anna Johnson BSc, MSc, PhD, . johnsona@iastate.edu. . Department of Animal Science,. Iowa State University. Ames, IA. 1. Objectives. Alexandre . Iscaife. ; Denis Reis Morais; Sabrina Thalita Reis; Nayara Izabel Viana, . Andre. . Bordini. ; Daniele . Janolli. ; Nelson . Dip. ; Miguel . Srougi. ; Katia Ramos Moreira Leite . Laboratory of Medical Research – LIM 55, Urology, University of Sao Paulo, Sao Paulo, Brazil. This program will include a discussion of . off-label treatments and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. . VeruInc The Prostate Cancer Company Novel MedicinesVeru Corporate PresentationJune 2020Thiscommunicationcontainsforward-lookingstatementswithinthemeaningofthePrivateSecuritiesLitigationReformActof1995 –. To treat . or not to treat. Dr Oliver Klein – Medical Oncologist. Prostate Cancer. |. . Epidemiology- Australia. Most common cancers 2012 . Cancer related deaths 2010 . Australian Institute of Health and Welfare. Sorting Out the Androgen Deprivation Therapy Options for Locally Advanced . CSPC. Supported by an educational grant from Astellas and Pfizer, Inc.. EPISODE 3. Cora N. Sternberg MD, FACP. Clinical Director, . . Using PSMA-PET for accurate staging in biochemical recurrent metastatic prostate cancer. . Case courtesy of Associate Professor Yao ZHU, Fudan University, Shanghai Cancer Center. Photo by . Hobi. Francesco GIAMMARILE. « . Aut tace aut loquere meliora silentio.  ». Bone scan and F-Choline . Radionuclide treatment . Presentation Outline. Introduction. NO CONFLICT OF INTEREST. General aspects. Clinical implementation of testing and PARP. i. monotherapy, and the patient journey for prostate cancer patients. Dr Neal Shore. , . MD, FACS. Carolina Urologic Research Center and Chief Medical Officer for Genesis Care, USA. Foundation Medicine. ctDNA. is good information for somatic mutations in . mCRPC. when biopsy is not possible. lots of other data on the importance of CTCs as predictive. 93% concordance for BRCA1/2 for tissue and liquid biopsy – . Jeanny B. Aragon-Ching, M.D., F.A.C.P.. Clinical Program Director of Genitourinary Cancers, Inova . Schar. Cancer Institute. Associate Professor of Medicine, Virginia Commonwealth University. October 13, 2018. nm. CRPC patients and the healthcare team. GUIDE COMMUNICATION FRAMEWORK - . Part 3. Dr.. Jason Alcorn, D. . Nurs. , FHEA, MSc, BSc. Mid Yorkshire Hospitals NHS Trust, UK. NOVEMBER 2021. nmCRPC, non-metastatic castration-resistant prostate cancer. nm. crpc and the implications of new . imaging modalities. Alexander Drzezga MD, PhD. Professor and Chair . Department of Nuclear Medicine, University Hospital of Cologne, Germany. David Pfister MD, PhD.